1.	PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation Phase: Phase IV Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: 20050100, NCT00352703
2.	A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer Phase: Phase III, Phase II Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 20040122, NCT00393822
3.	Phase III Randomized Study of Recombinant Human Keratinocyte Growth Factor in Reducing Therapy-Induced Oral Mucositis in Patients With Hematologic Malignancies Undergoing Total Body Irradiation and High-Dose Chemotherapy Followed By Autologous Peripheral Blood Stem Cell Transplantation Phase: Phase III Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0012064, AMGEN-KGF-20000162, FHCRC-1612.00, MSKCC-01065, NCI-G01-1961
4.	Palifermin for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer Phase: Phase III Type: Supportive care Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 20020402, NCT00101582
5.	A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer Phase: Phase III Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 20040118, NCT00131638
6.	Phase III Randomized Study of Palifermin for Reducing Oral Mucositis in Patients With Locally Advanced Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Hypopharynx, or Larynx Undergoing Concurrent Radiotherapy and Chemotherapy Phase: Phase III Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-0435, RTOG 0435, NCT00360971
7.	A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma Phase: Phase III Type: Supportive care, Treatment Status: Closed Age: 18 to 70 Sponsor: Other Protocol IDs: 20050219, NCT00434161
8.	Phase I/II Randomized Study of Recombinant Human Keratinocyte Growth Factor in Patients with Hodgkin's Disease and Non-Hodgkin's Lymphoma Undergoing High Dose Chemotherapy with Autologous Peripheral Blood Stem Cell Transplantation Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Closed Age: 16 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MSKCC-97112, AMGEN-KGF-960189, NCI-G97-1368
9.	Phase I/II Randomized Study of Recombinant Human Keratinocyte Growth Factor in Patients With Head and Neck Cancer Undergoing Chemoradiotherapy (Summary Last Modified 03/2000) Phase: Phase II, Phase I Type: Treatment Status: Closed Age: Adult Sponsor: NCI Protocol IDs: RPCI-DS-97-33, AMGEN-KGF-970149-08, NCI-G98-1397
10.	Phase II Randomized Study of Recombinant Human Keratinocyte Growth Factor in Patients with Hematologic Malignancies Undergoing Total Body Irradiation and High Dose Chemotherapy with Autologous Peripheral Blood Stem Cell Support Phase: Phase II Type: Supportive care, Treatment Status: Completed Age: 18 to 65 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MSKCC-99029, AMGEN-KGF-980231-04, NCI-G99-1574, NCT00004061
11.	Phase II Randomized Study of Recombinant Human Keratinocyte Growth Factor for Oral Mucositis in Patients With Hematologic Malignancies Undergoing Radiotherapy and High Dose Chemotherapy Prior to Autologous Peripheral Blood Stem Cell Transplantation Phase: Phase II Type: Supportive care, Treatment Status: Completed Age: 12 to 65 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-9812041, AMGEN-KGF-980231-03, NCI-G99-1609, NCT00004132
12.	Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Phase: Phase II Type: Supportive care Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 20030185, NCT00094861
13.	A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Palifermin (rHuKGF) in the Reduction of Acute Graft Versus Host Disease in Subjects With Hematologic Malignancies Undergoing Allogeneic Marrow/PBPC Transplantation Phase: Phase II Type: Supportive care Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 20040213, NCT00189488
14.	Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma Phase: Phase II Type: Supportive care Status: Completed Age: 18 to 65 Sponsor: Other Protocol IDs: 2004-0511, NCT00267046
15.	Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support Phase: Phase I Type: Supportive care Status: Completed Age: 18 to 76 Sponsor: Other Protocol IDs: 20010182, NCT00070616
16.	A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT Phase: Phase I Type: Treatment Status: Completed Age: 1 to 16 Sponsor: Other Protocol IDs: 20010133, NCT00460421
17.	Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma Phase: Phase I Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000547155, P30CA022453, WSU-2006-119, NCT00482846
18.	Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Phase: Phase I Type: Supportive care Status: Completed Age: 2 to 18 Sponsor: Other Protocol IDs: PALSCT, NCT00701688
19.	Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer Phase: No phase specified Type: Biomarker/Laboratory analysis, Supportive care Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: 2437.00, NCI-2010-01711, NCT01233921